{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:01:11Z","timestamp":1777687271845,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01416-0","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:41Z","timestamp":1777453061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CETP Renaissance with Obicetrapib"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-6257","authenticated-orcid":false,"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"2","key":"1416_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/01.atv.0000054658.91146.64","volume":"23","author":"PJ Barter","year":"2003","unstructured":"Barter PJ, Brewer HB Jr., Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160\u20137. https:\/\/doi.org\/10.1161\/01.atv.0000054658.91146.64.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"1416_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/j.1532-5415.2007.01275.x","volume":"55","author":"MC Silva","year":"2007","unstructured":"Silva MC, Janssens AC, Hofman A, Witteman JC, van Duijn CM. Cholesteryl ester transfer protein gene and coronary heart disease mortality: the Rotterdam study. J Am Geriatr Soc. 2007;55(9):1483\u20134. https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01275.x.","journal-title":"J Am Geriatr Soc"},{"key":"1416_CR3","doi-asserted-by":"publisher","unstructured":"Nelson AJ, Sniderman AD, Ditmarsch M, et al Cholesteryl Ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels. Int J Mol Sci. 2022;23(16). . https:\/\/doi.org\/10.3390\/ijms23169417","DOI":"10.3390\/ijms23169417"},{"issue":"21","key":"1416_CR4","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322. https:\/\/doi.org\/10.1056\/NEJMoa0706628.","journal-title":"N Engl J Med"},{"issue":"22","key":"1416_CR5","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1206797.","journal-title":"N Engl J Med"},{"issue":"20","key":"1416_CR6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1609581.","journal-title":"N Engl J Med"},{"issue":"13","key":"1416_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"HPS3\/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377(13):1217\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1706444.","journal-title":"N Engl J Med"},{"issue":"14","key":"1416_CR8","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","volume":"43","author":"E Sammons","year":"2022","unstructured":"Sammons E, Hopewell JC, et al. The HPS3\/TIMI55-REVEAL Collaborative Group, Writing Committee, Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022;43(14):1416\u201324. . https:\/\/doi.org\/10.1093\/eurheartj\/ehab863","journal-title":"Eur Heart J"},{"issue":"9992","key":"1416_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(15)60158-1.","journal-title":"Lancet"},{"issue":"8","key":"1416_CR10","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"issue":"5","key":"1416_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40256-025-00740-1","volume":"25","author":"JJP Kastelein","year":"2025","unstructured":"Kastelein JJP, Ditmarsch M, Hsieh A, et al. A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers. Am J Cardiovasc Drugs. 2025;25(5):693\u2013702. https:\/\/doi.org\/10.1007\/s40256-025-00740-1.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"1416_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503. https:\/\/doi.org\/10.1016\/j.jacl.2023.05.098.","journal-title":"J Clin Lipidol"},{"issue":"10491","key":"1416_CR13","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","volume":"405","author":"A Sarraju","year":"2025","unstructured":"Sarraju A, Brennan D, Hayden K, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(25)00721-4.","journal-title":"Lancet"},{"issue":"1","key":"1416_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025;393(1):51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2415820.","journal-title":"N Engl J Med"},{"key":"1416_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04179-4","author":"SJ Nicholls","year":"2026","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-025-04179-4.","journal-title":"Nat Med"},{"key":"1416_CR16","doi-asserted-by":"publisher","first-page":"101303","DOI":"10.1016\/j.ajpc.2025.101303","volume":"24","author":"B Araujo","year":"2025","unstructured":"Araujo B, Arrighini GS, Queiroga F, et al. Efficacy and safety of obicetrapib in patients with dyslipidemia: an updated meta-analysis of randomized controlled trials. Am J Prev Cardiol. 2025;24:101303. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101303.","journal-title":"Am J Prev Cardiol"},{"key":"1416_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2026.02.018","author":"A Matteucci","year":"2026","unstructured":"Matteucci A, Di Fusco SA, Bonanni M, et al. Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: A network meta-analysis. J Clin Lipidol. 2026. https:\/\/doi.org\/10.1016\/j.jacl.2026.02.018.","journal-title":"J Clin Lipidol"},{"issue":"14","key":"1416_CR18","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvab350.","journal-title":"Cardiovasc Res"},{"issue":"14","key":"1416_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","volume":"86","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ray KK, et al. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025;86(14):1046\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2025.07.056.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1416_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/BF02591657","volume":"21","author":"JJ Albers","year":"1992","unstructured":"Albers JJ, Tollefson JH, Wolfbauer G, Albright RE Jr. Cholesteryl ester transfer protein in human brain. Int J Clin Lab Res. 1992;21(3):264\u20136. https:\/\/doi.org\/10.1007\/BF02591657.","journal-title":"Int J Clin Lab Res"},{"issue":"6","key":"1416_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/BF00318577","volume":"90","author":"T Yamada","year":"1995","unstructured":"Yamada T, Kawata M, Arai H, Fukasawa M, Inoue K, Sato T. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer\u2019s disease brain tissues. Acta Neuropathol. 1995;90(6):633\u20136. https:\/\/doi.org\/10.1007\/BF00318577.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1416_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1471-4159.2004.02373.x","volume":"89","author":"Z Balazs","year":"2004","unstructured":"Balazs Z, Panzenboeck U, Hammer A, et al. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem. 2004;89(4):939\u201350. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02373.x.","journal-title":"J Neurochem"},{"issue":"23","key":"1416_CR23","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","volume":"299","author":"A Thompson","year":"2008","unstructured":"Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777\u201388. https:\/\/doi.org\/10.1001\/jama.299.23.2777.","journal-title":"JAMA"},{"issue":"12","key":"1416_CR24","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1212\/01.wnl.0000249116.50854.65","volume":"67","author":"N Barzilai","year":"2006","unstructured":"Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology. 2006;67(12):2170\u20135. https:\/\/doi.org\/10.1212\/01.wnl.0000249116.50854.65.","journal-title":"Neurology"},{"issue":"15","key":"1416_CR25","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1001\/jama.290.15.2030","volume":"290","author":"N Barzilai","year":"2003","unstructured":"Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003;290(15):2030\u201340. https:\/\/doi.org\/10.1001\/jama.290.15.2030.","journal-title":"JAMA"},{"issue":"1","key":"1416_CR26","doi-asserted-by":"publisher","first-page":"e547541","DOI":"10.1016\/j.neurobiolaging.2014.08.022","volume":"36","author":"C Lythgoe","year":"2015","unstructured":"Lythgoe C, Perkes A, Peterson M, et al. Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study. Neurobiol Aging. 2015;36(1):e547541\u2013543. . https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.08.022","journal-title":"Neurobiol Aging"},{"issue":"8","key":"1416_CR27","doi-asserted-by":"publisher","first-page":"e72537","DOI":"10.1371\/journal.pone.0072537","volume":"8","author":"L Sun","year":"2013","unstructured":"Sun L, Hu CY, Shi XH, et al. Trans-ethnical shift of the risk genotype in the CETP I405V with longevity: a Chinese case-control study and meta-analysis. PLoS ONE. 2013;8(8):e72537. https:\/\/doi.org\/10.1371\/journal.pone.0072537.","journal-title":"PLoS ONE"},{"issue":"2","key":"1416_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neulet.2007.05.013","volume":"420","author":"W Johnson","year":"2007","unstructured":"Johnson W, Harris SE, Collins P, Starr JM, Whalley LJ, Deary IJ. No association of CETP genotype with cognitive function or age-related cognitive change. Neurosci Lett. 2007;420(2):189\u201392. https:\/\/doi.org\/10.1016\/j.neulet.2007.05.013.","journal-title":"Neurosci Lett"},{"issue":"4","key":"1416_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00702-008-0180-y","volume":"116","author":"H Qureischie","year":"2009","unstructured":"Qureischie H, Heun R, Popp J, et al. Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions. J Neural Transm (Vienna). 2009;116(4):467\u201372. https:\/\/doi.org\/10.1007\/s00702-008-0180-y.","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"1416_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00415-005-0945-2","volume":"253","author":"E Rodriguez","year":"2006","unstructured":"Rodriguez E, Mateo I, Infante J, Llorca J, Berciano J, Combarros O. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer\u2019s disease risk associated with APOE epsilon4 allele. J Neurol. 2006;253(2):181\u20135. https:\/\/doi.org\/10.1007\/s00415-005-0945-2.","journal-title":"J Neurol"},{"key":"1416_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.02.006","author":"EE Sundermann","year":"2016","unstructured":"Sundermann EE, Wang C, Katz M, et al. Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein epsilon4 on memory decline in older adults. Neurobiol Aging. 2016. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.02.006. 41:200 e207-200 e212.","journal-title":"Neurobiol Aging"},{"key":"1416_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.brainres.2007.10.054","volume":"1187","author":"DW Chen","year":"2008","unstructured":"Chen DW, Yang JF, Tang Z, et al. Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer\u2019s disease as a modifier for APOE epsilon4 in Chinese. Brain Res. 2008;1187:52\u20137. https:\/\/doi.org\/10.1016\/j.brainres.2007.10.054.","journal-title":"Brain Res"},{"issue":"4","key":"1416_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/iub.448","volume":"63","author":"HC Oliveira","year":"2011","unstructured":"Oliveira HC, de Faria EC. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life. 2011;63(4):248\u201357. https:\/\/doi.org\/10.1002\/iub.448.","journal-title":"IUBMB Life"},{"issue":"1","key":"1416_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13195-024-01594-6","volume":"16","author":"AF Schmidt","year":"2024","unstructured":"Schmidt AF, Davidson MH, Ditmarsch M, Kastelein JJ, Finan C. Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimers Res Ther. 2024;16(1):228. https:\/\/doi.org\/10.1186\/s13195-024-01594-6.","journal-title":"Alzheimers Res Ther"},{"issue":"2011","key":"1416_CR35","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1101\/2024.11.05.621935","volume":"2024","author":"J Ph\u00e9nix","year":"2024","unstructured":"Ph\u00e9nix J, Sarty I, Katz MS, et al. Reducing CETP activity prevents memory decline in an Alzheimer\u2019s disease mouse model. bioRxiv. 2024;2024(2011):2005\u2013621935. https:\/\/doi.org\/10.1101\/2024.11.05.621935.","journal-title":"bioRxiv"},{"issue":"1","key":"1416_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","volume":"7","author":"LT Nordestgaard","year":"2022","unstructured":"Nordestgaard LT, Christoffersen M, Lauridsen BK, et al. Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population. JAMA Cardiol. 2022;7(1):55\u201364. https:\/\/doi.org\/10.1001\/jamacardio.2021.3728.","journal-title":"JAMA Cardiol"},{"key":"1416_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.dadm.2018.08.008","volume":"10","author":"GM van der Peloso","year":"2018","unstructured":"Peloso GM, van der Lee SJ, International Genomics of Alzheimer\u2019s P, Destefano AL, Seshardi S. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2018, 10:595\u2013598. https:\/\/doi.org\/10.1016\/j.dadm.2018.08.008","journal-title":"Alzheimers Dement (Amst)."},{"issue":"10","key":"1416_CR38","doi-asserted-by":"publisher","first-page":"e70638","DOI":"10.1002\/alz.70638","volume":"21","author":"LT Nordestgaard","year":"2025","unstructured":"Nordestgaard LT, Hanson A, Sanderson E, et al. Cholesterol-lowering drug targets reduce risk of dementia: Mendelian randomization and meta-analyses of 1 million individuals. Alzheimers Dement. 2025;21(10):e70638. https:\/\/doi.org\/10.1002\/alz.70638.","journal-title":"Alzheimers Dement"},{"key":"1416_CR39","doi-asserted-by":"publisher","first-page":"1171937","DOI":"10.3389\/fphar.2023.1171937","volume":"14","author":"J Phenix","year":"2023","unstructured":"Phenix J, Cote J, Dieme D, et al. CETP inhibitor evacetrapib enters mouse brain tissue. Front Pharmacol. 2023;14:1171937. https:\/\/doi.org\/10.3389\/fphar.2023.1171937.","journal-title":"Front Pharmacol"},{"issue":"47","key":"1416_CR40","doi-asserted-by":"publisher","first-page":"36958","DOI":"10.1074\/jbc.M110.127829","volume":"285","author":"TL Lewis","year":"2010","unstructured":"Lewis TL, Cao D, Lu H, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem. 2010;285(47):36958\u201368. https:\/\/doi.org\/10.1074\/jbc.M110.127829.","journal-title":"J Biol Chem"},{"issue":"5","key":"1416_CR41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jacl.2016.06.006","volume":"10","author":"JC van Capelleveen","year":"2016","unstructured":"van Capelleveen JC, Kastelein JJ, Zwinderman AH, et al. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. J Clin Lipidol. 2016;10(5):1137\u2013e11441133. https:\/\/doi.org\/10.1016\/j.jacl.2016.06.006.","journal-title":"J Clin Lipidol"},{"key":"1416_CR42","doi-asserted-by":"publisher","first-page":"700847","DOI":"10.3389\/fphys.2021.700847","volume":"12","author":"J Van Valkenburgh","year":"2021","unstructured":"Van Valkenburgh J, Meuret C, Martinez AE, et al. Understanding the Exchange of Systemic HDL Particles Into the Brain and Vascular Cells Has Diagnostic and Therapeutic Implications for Neurodegenerative Diseases. Front Physiol. 2021;12:700847. https:\/\/doi.org\/10.3389\/fphys.2021.700847.","journal-title":"Front Physiol"},{"issue":"2","key":"1416_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jnc.15170","volume":"159","author":"S Pedrini","year":"2021","unstructured":"Pedrini S, Chatterjee P, Hone E, Martins RN. High-density lipoprotein-related cholesterol metabolism in Alzheimer\u2019s disease. J Neurochem. 2021;159(2):343\u201377. https:\/\/doi.org\/10.1111\/jnc.15170.","journal-title":"J Neurochem"},{"issue":"1","key":"1416_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/jad-2008-13103","volume":"13","author":"W Wang","year":"2008","unstructured":"Wang W, Shinto L, Connor WE, Quinn JF. Nutritional biomarkers in Alzheimer\u2019s disease: the association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis. 2008;13(1):31\u20138. https:\/\/doi.org\/10.3233\/jad-2008-13103.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1416_CR45","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.tjpad.2025.100394","volume":"13","author":"MH Davidson","year":"2026","unstructured":"Davidson MH, Szarek M, Scheltens P, et al. Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026;13(1):100394. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100394.","journal-title":"J Prev Alzheimers Dis"},{"key":"1416_CR46","doi-asserted-by":"publisher","unstructured":"Niesor E, Rezzi S, Jaenggi P, Hodgson A, Ditmarsch M, Kastelein J Obicetrapib significantly increases plasma and high-density lipoprotein (HDL) levels of lipophilic antioxidants. Atherosclerosis. 2025;407(119560). . https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119560.","DOI":"10.1016\/j.atherosclerosis.2025.119560"},{"issue":"3","key":"1416_CR47","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.jacl.2025.04.163","volume":"19","author":"E Niesor","year":"2025","unstructured":"Niesor E, Rezzi S, Jaenggi P, Hodgson A, Ditmarsch M, Kastelein J. Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, APOE, and S1P in HDL subfractions. J Clin Lipidol. 2025;19(3):e113\u20134. https:\/\/doi.org\/10.1016\/j.jacl.2025.04.163.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1416_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","volume":"2","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Pare G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women\u2019s Genome Health Study. Circ Cardiovasc Genet. 2009;2(1):26\u201333. https:\/\/doi.org\/10.1161\/CIRCGENETICS.108.817304.","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"1416_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.numecd.2009.06.009","volume":"21","author":"L Lopez-Rios","year":"2011","unstructured":"Lopez-Rios L, Perez-Jimenez P, Martinez-Quintana E, et al. Association of Taq 1B CETP polymorphism with insulin and HOMA levels in the population of the Canary Islands. Nutr Metab Cardiovasc Dis. 2011;21(1):18\u201324. https:\/\/doi.org\/10.1016\/j.numecd.2009.06.009.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"1416_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199801083380203","volume":"338","author":"JA Kuivenhoven","year":"1998","unstructured":"Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338(2):86\u201393. https:\/\/doi.org\/10.1056\/NEJM199801083380203.","journal-title":"N Engl J Med"},{"issue":"2","key":"1416_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.atherosclerosis.2015.08.015","volume":"242","author":"C Koopal","year":"2015","unstructured":"Koopal C, van der Graaf Y, Asselbergs FW, Westerink J, Visseren FL, group Ss. Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. Atherosclerosis. 2015;242(2):605\u201310. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.08.015.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1416_CR52","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt AF, Hunt NB, Gordillo-Maranon M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640. https:\/\/doi.org\/10.1038\/s41467-021-25703-3.","journal-title":"Nat Commun"},{"issue":"6","key":"1416_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.diabet.2018.02.005","volume":"44","author":"W Masson","year":"2018","unstructured":"Masson W, Lobo M, Siniawski D, et al. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Diabetes Metab. 2018;44(6):508\u201313. https:\/\/doi.org\/10.1016\/j.diabet.2018.02.005.","journal-title":"Diabetes Metab"},{"key":"1416_CR54","doi-asserted-by":"publisher","unstructured":"Menon V, Kumar A, Patel DR, et al. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Res Care. 2020;8(1). https:\/\/doi.org\/10.1136\/bmjdrc-2019-000943.","DOI":"10.1136\/bmjdrc-2019-000943"},{"issue":"5","key":"1416_CR55","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2337\/dc19-2204","volume":"43","author":"GG Schwartz","year":"2020","unstructured":"Schwartz GG, Leiter LA, Ballantyne CM, et al. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020;43(5):1077\u201384. https:\/\/doi.org\/10.2337\/dc19-2204.","journal-title":"Diabetes Care"},{"issue":"6","key":"1416_CR56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","volume":"8","author":"K Dangas","year":"2022","unstructured":"Dangas K, Navar AM, Kastelein JJP. The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):622\u201332. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac025.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"4","key":"1416_CR57","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrendo.2011.235","volume":"8","author":"BG Drew","year":"2012","unstructured":"Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012;8(4):237\u201345. https:\/\/doi.org\/10.1038\/nrendo.2011.235.","journal-title":"Nat Rev Endocrinol"},{"issue":"15","key":"1416_CR58","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.108.843219","volume":"119","author":"BG Drew","year":"2009","unstructured":"Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119(15):2103\u201311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.843219.","journal-title":"Circulation"},{"key":"1416_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fphar.2015.00258","volume":"6","author":"AL Siebel","year":"2015","unstructured":"Siebel AL, Heywood SE, Kingwell BA. HDL and glucose metabolism: current evidence and therapeutic potential. Front Pharmacol. 2015;6:258. https:\/\/doi.org\/10.3389\/fphar.2015.00258.","journal-title":"Front Pharmacol"},{"key":"1416_CR60","doi-asserted-by":"publisher","unstructured":"Niesor E, Ditmarsch M, Rezzi S, et al. Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies. Am Heart J. 2024;278. . https:\/\/doi.org\/10.1016\/j.ahj.2024.09.014","DOI":"10.1016\/j.ahj.2024.09.014"},{"issue":"2","key":"1416_CR61","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144\u201360. https:\/\/doi.org\/10.1016\/S2214-109X(20)30489-7.","journal-title":"Lancet Glob Health"},{"issue":"39","key":"1416_CR62","doi-asserted-by":"publisher","first-page":"13601","DOI":"10.1074\/jbc.RA119.012305","volume":"295","author":"UL Kelly","year":"2020","unstructured":"Kelly UL, Grigsby D, Cady MA, et al. High-density lipoproteins are a potential therapeutic target for age-related macular degeneration. J Biol Chem. 2020;295(39):13601\u201316. https:\/\/doi.org\/10.1074\/jbc.RA119.012305.","journal-title":"J Biol Chem"},{"issue":"3","key":"1416_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ophtha.2018.09.045","volume":"126","author":"JM Colijn","year":"2019","unstructured":"Colijn JM, den Hollander AI, Demirkan A, et al. Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia. Ophthalmology. 2019;126(3):393\u2013406. https:\/\/doi.org\/10.1016\/j.ophtha.2018.09.045.","journal-title":"Ophthalmology"},{"issue":"6","key":"1416_CR64","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/ije\/dyx189","volume":"46","author":"Q Fan","year":"2017","unstructured":"Fan Q, Maranville JC, Fritsche L, et al. HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization. Int J Epidemiol. 2017;46(6):1891\u2013902. https:\/\/doi.org\/10.1093\/ije\/dyx189.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1416_CR65","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ophtha.2024.12.039","volume":"132","author":"JS Chen","year":"2025","unstructured":"Chen JS, Esko JD, Walker E, Gordts P, Baxter SL, Toomey CB. High-Density Lipoproteins Associated with Age-Related Macular Degeneration in the All of Us Research Program. Ophthalmology. 2025;132(6):684\u201391. https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.039.","journal-title":"Ophthalmology"},{"issue":"3","key":"1416_CR66","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ajo.2014.05.027","volume":"158","author":"R Klein","year":"2014","unstructured":"Klein R, Myers CE, Buitendijk GH, et al. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. Am J Ophthalmol. 2014;158(3):513\u2013e524513. https:\/\/doi.org\/10.1016\/j.ajo.2014.05.027.","journal-title":"Am J Ophthalmol"},{"key":"1416_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.gene.2017.09.022","volume":"636","author":"R Liutkeviciene","year":"2017","unstructured":"Liutkeviciene R, Vilkeviciute A, Streleckiene G, Kriauciuniene L, Chaleckis R, Deltuva VP. Associations of cholesteryl ester transfer protein (CETP) gene variants with predisposition to age-related macular degeneration. Gene. 2017;636:30\u20135. https:\/\/doi.org\/10.1016\/j.gene.2017.09.022.","journal-title":"Gene"},{"issue":"2","key":"1416_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134\u201343. https:\/\/doi.org\/10.1038\/ng.3448.","journal-title":"Nat Genet"},{"issue":"1","key":"1416_CR69","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12920-020-00760-7","volume":"13","author":"TW Winkler","year":"2020","unstructured":"Winkler TW, Grassmann F, Brandl C, et al. Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease. BMC Med Genomics. 2020;13(1):120. https:\/\/doi.org\/10.1186\/s12920-020-00760-7.","journal-title":"BMC Med Genomics"},{"key":"1416_CR70","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1038\/ncomms7063","volume":"6","author":"CY Cheng","year":"2015","unstructured":"Cheng CY, Yamashiro K, Chen LJ, et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat Commun. 2015;6:6063. https:\/\/doi.org\/10.1038\/ncomms7063.","journal-title":"Nat Commun"},{"issue":"8","key":"1416_CR71","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.ophtha.2017.03.042","volume":"124","author":"S Burgess","year":"2017","unstructured":"Burgess S, Davey Smith G. Mendelian Randomization Implicates High-Density Lipoprotein Cholesterol-Associated Mechanisms in Etiology of Age-Related Macular Degeneration. Ophthalmology. 2017;124(8):1165\u201374. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.042.","journal-title":"Ophthalmology"},{"issue":"1","key":"1416_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamacardio.2017.4177","volume":"3","author":"IY Millwood","year":"2018","unstructured":"Millwood IY, Bennett DA, Holmes MV, et al. Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. JAMA Cardiol. 2018;3(1):34\u201343. https:\/\/doi.org\/10.1001\/jamacardio.2017.4177.","journal-title":"JAMA Cardiol"},{"key":"1416_CR73","doi-asserted-by":"publisher","first-page":"15711","DOI":"10.1038\/srep15711","volume":"5","author":"YF Wang","year":"2015","unstructured":"Wang YF, Han Y, Zhang R, Qin L, Wang MX, Ma L. CETP\/LPL\/LIPC gene polymorphisms and susceptibility to age-related macular degeneration. Sci Rep. 2015;5:15711. https:\/\/doi.org\/10.1038\/srep15711.","journal-title":"Sci Rep"},{"issue":"1","key":"1416_CR74","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ije\/dyaa178","volume":"50","author":"X Han","year":"2021","unstructured":"Han X, Ong JS, Hewitt AW, Gharahkhani P, MacGregor S. The effects of eight serum lipid biomarkers on age-related macular degeneration risk: a Mendelian randomization study. Int J Epidemiol. 2021;50(1):325\u201336. https:\/\/doi.org\/10.1093\/ije\/dyaa178.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"1416_CR75","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jacc.2022.06.007","volume":"80","author":"BA Ference","year":"2022","unstructured":"Ference BA. Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies. J Am Coll Cardiol. 2022;80(7):663\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.007.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"1416_CR76","doi-asserted-by":"publisher","first-page":"e031459","DOI":"10.1161\/JAHA.123.031459","volume":"12","author":"C Yu","year":"2023","unstructured":"Yu C, Bakshi A, Watts GF, et al. Genome-Wide Association Study of Cardiovascular Resilience Identifies Protective Variation in the CETP Gene. J Am Heart Assoc. 2023;12(21):e031459. https:\/\/doi.org\/10.1161\/JAHA.123.031459.","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"1416_CR77","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","volume":"43","author":"W Committee","year":"2022","unstructured":"HPS3\/TIMI55-REVEAL Collaborative Group, Committee W, Sammons E et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022;43(14):1416\u201324. https:\/\/doi.org\/10.1093\/eurheartj\/ehab863","journal-title":"Eur Heart J"},{"issue":"15","key":"1416_CR78","doi-asserted-by":"publisher","first-page":"e1801046","DOI":"10.1002\/mnfr.201801046","volume":"63","author":"EH Harrison","year":"2019","unstructured":"Harrison EH. Mechanisms of Transport and Delivery of Vitamin A and Carotenoids to the Retinal Pigment Epithelium. Mol Nutr Food Res. 2019;63(15):e1801046. https:\/\/doi.org\/10.1002\/mnfr.201801046.","journal-title":"Mol Nutr Food Res"},{"key":"1416_CR79","doi-asserted-by":"publisher","first-page":"106972","DOI":"10.1016\/j.phrs.2023.106972","volume":"197","author":"N Mehta","year":"2023","unstructured":"Mehta N, Dangas K, Ditmarsch M, Rensen PCN, Dicklin MR, Kastelein JJP. The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease. Pharmacol Res. 2023;197:106972. https:\/\/doi.org\/10.1016\/j.phrs.2023.106972.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1416_CR80","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.5551\/jat.RV22020","volume":"31","author":"Y Endo","year":"2024","unstructured":"Endo Y, Sasaki K, Ikewaki K. Bridging the Gap Between the Bench and Bedside: Clinical Applications of High-density Lipoprotein Function. J Atheroscler Thromb. 2024;31(9):1239\u201348. https:\/\/doi.org\/10.5551\/jat.RV22020.","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"1416_CR81","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/CIRCULATIONAHA.120.048568","volume":"143","author":"M Trinder","year":"2021","unstructured":"Trinder M, Wang Y, Madsen CM, et al. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Circulation. 2021;143(9):921\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048568.","journal-title":"Circulation"},{"issue":"5","key":"1416_CR82","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.tem.2020.01.003","volume":"31","author":"LL Blauw","year":"2020","unstructured":"Blauw LL, Wang Y, Willems van Dijk K, Rensen PCN. A novel role for CETP as immunological gatekeeper: raising HDL to cure sepsis? Trends Endocrinol Metab. 2020;31(5):334\u201343. https:\/\/doi.org\/10.1016\/j.tem.2020.01.003.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"1416_CR83","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2362.2010.02269.x","volume":"40","author":"CM Grion","year":"2010","unstructured":"Grion CM, Cardoso LT, Perazolo TF, et al. Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients. Eur J Clin Invest. 2010;40(4):330\u20138. https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02269.x.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"1416_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1194\/jlr.E012138","volume":"52","author":"KR Feingold","year":"2011","unstructured":"Feingold KR, Grunfeld C. The role of HDL in innate immunity. J Lipid Res. 2011;52(1):1\u20133. https:\/\/doi.org\/10.1194\/jlr.E012138.","journal-title":"J Lipid Res"},{"issue":"7","key":"1416_CR85","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1164\/rccm.201806-1157OC","volume":"199","author":"M Trinder","year":"2019","unstructured":"Trinder M, Genga KR, Kong HJ, et al. Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. Am J Respir Crit Care Med. 2019;199(7):854\u201362. https:\/\/doi.org\/10.1164\/rccm.201806-1157OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1416_CR86","doi-asserted-by":"publisher","first-page":"16764","DOI":"10.1038\/s41598-018-35261-2","volume":"8","author":"KR Genga","year":"2018","unstructured":"Genga KR, Trinder M, Kong HJ, et al. CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. Sci Rep. 2018;8(1):16764. https:\/\/doi.org\/10.1038\/s41598-018-35261-2.","journal-title":"Sci Rep"},{"issue":"8","key":"1416_CR87","doi-asserted-by":"publisher","first-page":"100858","DOI":"10.1016\/j.jlr.2025.100858","volume":"66","author":"H Deng","year":"2025","unstructured":"Deng H, Liang WY, Chen L, et al. High-density lipoprotein attenuates lipopolysaccharide-induced IL-1beta activation via scavenger receptor class B type 1. J Lipid Res. 2025;66(8):100858. https:\/\/doi.org\/10.1016\/j.jlr.2025.100858.","journal-title":"J Lipid Res"},{"issue":"2","key":"1416_CR88","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40265-025-02275-w","volume":"86","author":"M Naim","year":"2026","unstructured":"Naim M, Sumida K, Streja E, et al. Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol. Drugs. 2026;86(2):177\u2013202. https:\/\/doi.org\/10.1007\/s40265-025-02275-w.","journal-title":"Drugs"},{"key":"1416_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2026.101532","author":"L Vogt","year":"2026","unstructured":"Vogt L, Davidson MH, Szarek M, et al. Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials. Am J Prev Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.ajpc.2026.101532.","journal-title":"Am J Prev Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01416-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01416-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01416-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:43Z","timestamp":1777453063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01416-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1416"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01416-0","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"AP has nothing to disclose. ALC has received honoraria, lecture fees, or research grants from Amarin, Amgen, Astrazeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, Viatris outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"43"}}